Leprosy remains a significant problem in many countries. Despite effective treatment of the infection many individuals will develop painful, inflammatory episodes with treatment raising many issues.
The ENLIST group consists of 8 institutes based across seven countries, on 4 continents, co-ordinated by LSHTM in London.
Leprosy is caused by the bacterium Mycobacterium leprae and remains a significant problem in many countries. The treatment of the infection requires multi drug therapy for 6 or 12 months which is very effective. However, despite treatment of the infection many individuals will develop painful, inflammatory episodes which may cause permanent damage to nerves and other organs, often causing permanent disability. This is known as Erythema nodosum leprosum (ENL) and can effect up to 40% of leprosy patients.
The treatment of ENL is usually with steroids which have many adverse effects when given for prolonged periods in the high doses required. Thalidomide, which is effective, is not widely available and is banned in many leprosy endemic countries. The ENLIST group aims to:
- Improve the understanding of the mechanisms which cause ENL
- Improve the evidence used to guide treatment decisions
- Improve access to effective treatments
We are conducting two double blind randomised clinical trials to determine if methotrexate (an immunosuppressant) improves the outcomes for individuals with these severe episodes of inflammation.
Leprosy is an infectious disease which has been around since biblical times. It is spread through contact with nose and mouth droplets of an infected and untreated person. The symptoms of leprosy include disfiguring skin sores, lumps and bumps as well as nerve damage in the arms and legs. This nerve damage can lead to loss of feeling in the hands and feet so sufferers do not feel pain when they are injured, leading to further possibilities of infection and damage.
Leprosy is now a curable disease. Treatment usually consists of two or more antibiotics (multi-drug therapy) over a course of 6-12 months. Anti-inflammatory drugs may also be taken to reduce the nerve pain and damage caused by leprosy.
There is a huge amount of stigma surrounding leprosy mostly due to a lack of understanding about how the disease is transmitted and due to the disfigurements it can cause. In many poor and developing countries it has long been believed that leprosy is inherited and punishment for past misdeeds. In the past many communities have shunned leprosy suffers, creating isolated colonies to quarantine patients.
Due to the stigma surrounding leprosy many sufferers delay seeking medical advice when symptoms appear. This can delay treatment and cause unnecessary suffering and deformities. There are now many organisations working around the globe to educate communities on the facts of leprosy and its treatment.
We are clinicians and laboratory scientists with extensive experience in the treatment and investigation of the causes of ENL. We are based at institutions in six countries on four continents. The group is coordinated from London and includes five centres in the two countries with highest rates of leprosy: India and Brazil.
The ENLIST group would benefit form support for the network, supporting work in India, promoting web based data collection, collecting data on severity, testing new anti-inflammatory drugs.
In addition to India and Brazil ENLIST members are also based in Bangladesh, Ethiopia, Nepal and the Philippines. We are hoping to recruit further centres in Indonesia and Mali in the near future.
Find more about the LSHTM team below:
The ENLIST project receives funding from 3 different European organisations: the Leprosy Research Initiative (LRI), Hospital & Homes of St Giles and the Turing Foundation.
The Leprosy Research Initiative is a combined venture of ILEP members and closely associated partners, which was launched in 2013, with the preamble to establish a joint fund to support leprosy research and mechanisms to access external funding.
The Hospital and Homes of St Giles charity was started in 1914 to provide a place of respite for those who had contracted leprosy during service in the British Empire and for many years was run by sisters of the Community of the Sacred Passion as nurses. Numbers of both nuns and patients had declined by the late 1970s and the decision was taken to sell the site in East Hanningfield, Essex, to a housing association with an agreement that the residual patients could continue to live there and an amount of money. The Trustees of the Charity then decided to spend the income from the resulting investments on sponsoring research into leprosy and thus started a long term relationship with the London School of Hygiene and Tropical Medicine. The assets of the charity have been declining over time in recognition of the need to maintain research spending but the Trustees are firmly of the view that spending on research is the best possible use of the Charity’s money.
The Turing Foundation was founded in july 2006 by Pieter and Françoise Geelen. The name of the foundation honours Alan Turing (1912-1954), the British scientist who is regarded by many as the founder of modern computer science. Turing has always been one of the heroes of Pieter Geelen. When Geelen and a friend who studied computer science together started a company in 1991, they named it the Turing Machine Company. In 2005 this company was renamed TomTom and it was listed on the Dutch stock exchange. From the proceeds of that IPO, Pieter and Françoise Geelen started the Turing Foundation. Upon the formation, Pieter and Françoise Geelen chose four objectives for the foundation’s funding strategy: education, art, nature conservation and leprosy research.
Jose Augusto da Costa Nery
Associate Researcher in Public Health of the Leprosy Laboratory (LAHAN) of the Oswaldo Cruz Institute, Oswaldo Cruz Foundation - FIOCRUZ, Rio de Janeiro. He has a PhD in Medicine (Infectious and Parasitic Diseases - DIP) from the Federal University of Rio de Janeiro - UFF (1995) and a PhD in Medicine (Infectious and Parasitic Diseases - DIP) UFRJ (2000). Professor of Dermatology at the Estácio de Sá University and the Institute of Dermatology Prof. Rubem David Azulay of the Santa Casa da Misericórdia in Rio de Janeiro. Professional with experience in clinical and therapeutic research, with emphasis on infectious diseases, acting mainly in the following pathologies: Leprosy; Sexually Transmitted Diseases and HIV.
For more information:
C Ruth Butlin CBE, MA, MB BCh
Current Designation: Honorary Medical advisor to DBLM hospital & Rural Health Programme, of The Leprosy Mission International, Bangladesh.
Past experience: over 30 years working in leprosy in 3 countries (India, Nepal, Bangladesh)
Areas of special interest: preventing and managing disability, teaching and training of health workers for comprehensive management of leprosy.
Publications: author/co-authorship of many papers and conference presentations on subjects related to leprosy, including drug resistance, clinical aspects, disease control, chemotherapy, disability and assessment of reactions.
Member of Editorial Board of The Leprosy Review.
Member of ENLIST consortium since 2014.
Special awards: CBE in Birthday honours list 2001.
Dr. Benjamin Jewel Rozario
Residential Medical Officer, DBLM Hospital Program, The Leprosy Mission Int’l-Bangladesh.
Responsible for medical care and medical services of DBLM Hospital including surgery, and with the team of staff work towards holistic care of people affected by leprosy or other disabilities. Responsible for supervising all medical, surgical and disability services, providing necessary supervision for physiotherapy technicians and assistive device section, laboratory and nursing department and responsible for usage of budget. Also responsible for facilitating good understanding and smooth cooperation between all different persons involved in the project and other relevant stakeholders, including local officials in health and civil administration, and other NGOs who refer patients to DBLM Hospital.
Marivic F. Balagon , M.D.
Leonard Wood Memorial
Center for TB and Leprosy Research
Armi A. Maghanoy, M.D.
Chief, Epidemiology Branch
Leonard Wood Memorial
Center for TB and Leprosy Research
Dr Joydeepa Darlong
Deputy Medical Superintendent, The Leprosy Mission Home and Hospital. Purulia Hospital – India
Providing Leadership role to the Unit and involvement in the clinical management, training to young doctors and research activities of the Unit.
ALERT Center, Addis Ababa, Ethiopia
Dr Shimelis Doni
Currently I am working as a clinician and head of Dermatology Department at ALERT Hospital.
Primary Affiliation: All African Leprosy and Dermatology Education and Training Center - Addis Ababa , 14 , Ethiopia
Research Interests: Leprosy, dermatology and seal transmitted infection
Dr Saba Lambert
Registered doctor with a licence to practice in Ethiopia. She has have worked in Ethiopia for 8 years, 6 of which were based at ALERT Hospital under a research project sponsored by the London School of Hygiene and Tropical Medicine, for which she obtained her PhD in 2015. During her time at ALERT, she worked with AHRI on various projects, was involved in teaching in the ALERT training centre on leprosy courses, was a founding member of the LEAG (Leprosy Expert Advisory Group) and was involved in many leprosy projects with the Ministry of Health (Leprosy Mapping and Leprosy Referral Centres Assessment and Strengthening). She has presented the ALERT work at many international conferences. She has a passion for her work in Leprosy and especially for ALERT.
Anandaban Hospital, Nepal
Dr. Deanna Hagge, Ph.D.
Research Scientist, Nepal. She is the Research Director of the Mycobacterial Research Laboratories (MRL) at Anandaban, a tertiary leprosy referral hospital in Kathmandu, Nepal where she has worked since 2007. Previously, she spent a decade in leprosy laboratory research with the Molecular Biology and Immunology Departments of the U.S. Department of Health and Human Services National Hansen’s Disease Programs. She acts as the onsite coordinator for several international collaborative research projects as well as primary clinical and laboratory studies. Leprosy research areas include: clinical trials, immunological complications, drug resistance, medical chart reviews, patient surveys, diagnostics, neuropathy, genetic susceptibility, transmission and helminth co-infections.
Dr Soetomo General Hospital, Surabaya, Indonesia
Dr. M. Yulianto Listiawan, Sp.KK(K), FINSDV, FAADV
Dermatovenereologist Consultant and Vice President in Education & Profession of The Indonesian Society of Dermatology and Venereology. Chairman of Indonesia Aesthetic Laser Study
Dr Medhi Denisa Alinda
Dermatologist from Surabaya, Indonesia, who works in the Leprosy Division. She graduated from the Universitas Airlangga Medical Faculty in 2014, she was the youngest graduate. Dr. Medhi has been practising in the Department of Venereology Dr. Soetomo Hospital, one of the referral hospital in East Java. Her practice focuses on Leprosy at the Dr. Soetomo Hospital and the Tropical Disease Centre. She also often fills a charity event for leprosy patients and for general practitioners. Currently she has already been part in many research projects about leprosy.
DR VIVEK VASUDEV PAI, DIRECTOR, BOMBAY LEPROSY PROJECT
- Medical Officer in Bombay Leprosy Project for 1987 to 1993.
- Assistant Director in Bombay Leprosy Project since 1993 to March 1996.
- Dy Director in Bombay Leprosy Project April 1996 to 2004.
- Addl. Director in Bombay Leprosy Project since January 2004 and currently Director since February 2007 till date.
Methotrexate and Prednisolone studies in Erythema Nodosum Leprosum (MaPs in ENL)
Methotrexate and Prednisolone studies (MaPs) in ENL. Leprosy remains a significant problem in many countries. Leprosy is caused by the bacterium Mycobacterium leprae. The treatment of the infection requires antimicrobial therapy for 6 or 12 months which is very effective. However, despite treatment of the infection many individuals will develop painful, inflammatory episodes which may cause permanent damage to nerves and other organs. This often causes permanent disability.
The treatment of these inflammatory episodes is usually with steroids which have many adverse effects when given for the prolonged periods in the high doses required. Thalidomide which is effective is not widely available and is banned in many leprosy endemic countries. We are conducting two double blind randomised clinical trials to determine if methotrexate (an immunosuppressant) improves the outcomes for individuals with these severe episodes of inflammation.
Primary LCNTDR organisation
LCNTDR Research team
- The Leprosy Mission Bangladesh FIOCRUZ, Rio de Janeiro, Brazil
- ALERT Center, Addis Ababa, Ethiopia
- Bombay Leprosy Project, Mumbai, India
- The Leprosy Mission India
- Dr Soetomo General Hospital, Surabaya, Indonesia
- Anandaban Hospital, Kathmandu, Nepal
- Leonard Wood Memorial Center for TB and Leprosy Research, Cebu, Philippines
- Hospital and Homes of St. Giles
- Leprosy Research Initiative
The ENLIST group regularly publishes in journals like the Leprosy Review and PLOS. Below is an overview of our publications.
A leprosy clinical severity scale for erythema nodosum leprosum: An international, multicentre validation study of the ENLIST ENL Severity Scale
Published in PLOS - July 2017
Erythema nodosum leprosum (ENL) is a severe, painful complication of leprosy, which can occur before, during or after successful treatment of the infection. ENL is characterised by severe pain and the development of new painful skin lesions. Other organ systems are often affected. ENL may continue to affect people for many years leading to disability, significant loss of income and sometimes death. ENL often requires prolonged treatment with corticosteroids, thalidomide or other drugs that modulate the immune system. Thalidomide is the most effective treatment but is not widely available or affordable in many leprosy endemic settings. This results in many people taking high doses of corticosteroids for prolonged periods and being at risk of severe adverse effects. In order to assess the efficacy of different treatments for ENL it is important to be able to compare individuals before and after treatment. This is difficult to do in a complex, multi-system disorder such as ENL. To overcome this problem we have developed a scale, which is easy to use, to measure the severity of ENL. In this article, we describe the validation of this scale, which ensures that it is a useful measure of ENL severity.
The development of a severity scale for Erythema Nodosum Leprosum—the ENLIST ENL severity scale.
Published in Leprosy Review - September 2016
Introduction: Erythema nodosum leprosum (ENL) is a severe, multi-system complication of leprosy which is difficult to manage. The evidence for effective treatment is limited and defining outcome measures for clinical trials is difficult. There are no validated measures of disease severity and so we wished to develop a clinical severity scale. Methods: Three published scales that had been used in ENL research were applied to patients with ENL at six leprosy referral centres. An analysis of the clinical features associated with ENL severity was performed on data obtained from the ENLIST 1 study. A meeting of experienced leprosy researchers was held to incorporate the findings from the scale testing and data analysis into a clinical severity scale for ENL Results: None of the three scales used were found to be ideal but some features of each were incorporated into a new scale along with novel items felt to be appropriate. A final 16 item scale--the ENLIST ENL Severity Scale was agreed by the meeting participants and detailed notes and definitions developed. Conclusions: We have developed a new severity measure for ENL which we propose to subject to formal validation.
ENLIST 1: An International Multi-centre Cross-sectional Study of the Clinical Features of Erythema Nodosum Leprosum.
Published in PLOS - September 2015
Leprosy is caused by a bacterium and is curable with a combination of antibiotics known as multi-drug therapy, which patients take for six or 12 months. However, a significant proportion of leprosy patients experience severe inflammation in their skin, nerves and other organs known as erythema nodosum leprosum (ENL). ENL is a severe complication of leprosy which can occur before, during, or after completion of antibacterial treatment. ENL causes severe morbidity affecting not only the skin, but also bones, joints, eyes, nerves, testes and kidneys. ENL may be fatal and it has been shown that the adverse effects of corticosteroid treatment also contribute to mortality. An effective treatment for ENL is thalidomide but this is not available in many leprosy endemic countries or is severely constrained by availability, cost and justified concerns about teratogenicity. Thalidomide, despite its effectiveness, is rarely used as a first line agent. Other effective drugs need to be identified to reduce the burden of this condition. In order to establish which treatments will be effective in ENL it is necessary to have a clear picture of the clinical features of the disease and how these influence severity. This is the first systematic study of ENL to define these and will help in developing tools to facilitate treatment studies of this severe, debilitating complication of leprosy.
Research Degree Poster Day at LSHTM
The Research Degrees Poster Day is an annual School-wide event, with students from each of the three faculties presenting posters on their research topic. All doctoral students are expected to present a poster at this event at least once during their course of studies.
Barbara De Barros presented her poster on the protocol currently being developed by ENLIST. This new study will evaluate the impact of using methotrexate in ENL treatment.
ENLIST meeting in Kathmandu - November 2018
The fifth ENLIST meeting was hosted by Dr. Deanna Hagge, Dr. Mahesh Shah and Dr. Indra Napit at the Ambassador Hotel and at Anandaban Hospital, Kathmandu, Nepal. The meeting took place on the 12th, 13th and 14th November 2018.
Collaborators from Bangladesh, Brazil, Ethiopia, India, Indonesia, Nepal and UK were present. The objectives of the meeting was to review the ENLIST –Methotrexate clinical trial protocol and start planning the start of the study. 2019 will be a very exciting year for the ENLIST group, all centres will start recruitment, which will take 2 years.